Summary
Introduction
The measurement of the fraction of nitric oxide in exhaled air (FE NO ) is an indirect means of assessing airway inflammation. 1 FE NO levels provide information enabling the clinician to interpret the aetiology of non-specific respiratory symptoms and the potential for steroid response. 2 In asthma, symptoms and airway inflammation may be discordant, 3 and both high and low FE NO measurements may help to discriminate between inflammatory and noninflammatory causes of airway symptoms. Serial measurements may allow for a more informed perspective in individual patients. 4, 5 Against this background, there is a need for an inexpensive analyser which provides accurate and reproducible results. Analysers based on chemiluminescence technology are expensive, and between-analyser differences in performance characteristics have been reported. 6, 7 The NIOX MINO Ò analyser (Aerocrine, Solna, Sweden) is based on electrochemical FE NO measurements. 8 Its performance in relation to chemiluminescence analysers has been evaluated in numerous studies. 5,9e19 Correlations between FE NO obtained using the NIOX MINO Ò and the NIOX Ò , 5,9,11,14e16,18 the Logan LR2000, 17 the Ecomedics CLD88sp 10, 12, 19 and the Sensormedics NOA 13 are highly significant, at approximately 0.95. The limits of agreement across studies vary between AE3.7 18 and AE4.8 ppb. 9 However, in almost all studies, only a single NIOX MINO Ò device has been tested. There are no studies in which multiple devices have been evaluated. In some, the NIOX MINO Ò has yielded consistently higher FE NO levels than with chemiluminescence analysers. 5, 10, 11, 13 In one report a correction factor was recommended. 18 It has also been reported that reproducibility may be less satisfactory in patients with high FE NO . 15 In contrast to chemiluminescence analysers, the electrochemical technology which supports the NIOX MINO Ò does not allow for pre-test calibration. Further, each analyser contains a replaceable sensor, and depending on specification, individual sensors are changed after 100 or 300 actuations. The sensitivity, precision, accuracy and measurement range of each sensor is pre-set to comply with published technical specifications. Thereafter, the operating instructions for the NIOX MINO Ò include a validation procedure using biological controls as a reference. This is designed to ensure that the performance characteristics conform to the manufacturer's specifications i.e. AE 5 ppb for values <50 ppb, AE10% for values >50 ppb (see http:// www.aerocrine.com/en/niox-mino/Specification/). However, in the absence of regular calibration, the exact performance characteristics of an analyser might potentially change over time or when a sensor is replaced.
To date, no data reporting the long term performance of the NIOX MINO Ò have been published, nor are there any data comparing individual sensors. The aim of the present study was to assess the long term stability and reproducibility of FE NO measurements using 24 NIOX MINO Ò sensoranalyser devices in patients with both high and low FE NO levels. This information is particularly relevant to clinicians who are measuring serial FE NO measurements to monitor patients with asthma using the NIOX MINO Ò , and to researchers using the device in field studies.
Subjects and methods
Subjects were non-smokers, and all but one had stable asthma. The other subject was atopic but asymptomatic and had a high baseline FE NO . Subjects taking regular inhaled corticosteroids continued to do so without any dose change during the study. There was a balanced number of subjects with high and low at baseline (>50 ppb and <30 ppb respectively). These FE NO cut-points were chosen because they correspond to mean levels associated with steroid responsiveness 2 or are at the upper limit of normal in patients with stable asthma. 20 Each subject gave written informed consent and the protocol was approved by the Lower South Island (NZ) Ethics Committee.
Subjects attended on three occasions at the same time of day. At each study visit, the mean of two FE NO measurements using a NIOX Ò (Aerocrine, Solna, Sweden) chemiluminescence analyser (the "gold standard") was initially obtained. The NIOX Ò was calibrated regularly in accordance with the manufacturer's instructions. The measurement technique complied with ATS/ERS guidelines. 21 The study design is described in Fig. 1 . Subjects were randomised into two groups (Group 1, n Z 8; Group 2, The sensor-analyser combinations were used without subsequent change throughout study.
Group 2, n = 9 (baseline FENO: >50ppb, n = 6; <30ppb, n = 3)
Analysers A-L, sensors [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The sensor-analyser combinations were used without subsequent change throughout study. n Z 9). There were 12 analysers (A-L) and 24 sensors (1e24), and thus a total of 24 different sensor-analyser combinations were evaluated. Group 1 patients were allocated to undertake two FE NO measurements from each of 12 NIOX MINO Ò sensor-analyser combinations at each visit, and Group 2 patients did likewise, using the same analysers but 12 different sensors. The order in which the sensoranalyser combinations were tested was randomised at each visit. The mean of the two measured values was recorded. The allocation of patients to sensor-analyser combinations was fixed for the duration of the study. Identical study procedures were undertaken at visits 2 and 3 after intervening intervals of approximately 1 and 2 months.
Quality control procedures were carried out on each NIOX MINO Ò device according to the manufacturer's guidelines. These were:
1. External control: FE NO results from a biological control (whose FE NO was in the range 5e40 ppb) were obtained on the study day and compared with the mean of three previous recordings. The result was required to be within AE10 ppb of the established mean value (3 occasions over 7 days). This was performed at each study visit. 2. Nitric oxide-free air was sampled using the quality control filter, to ensure that a result below the lower limit of detection (<5 ppb) was achieved. This was performed after every 45 actuations, or 7 days whichever came first. 3. Internal control: exhaled breaths were simulated using an electronic signal at 15 ppb and 75 ppb i.e. normal and high FE NO levels. This was performed after 45 actuations or 7 days, whichever came first.
Spirometric measurements were obtained at the end of each study visit: where a change in the FEV 1 of more than 20% occurred between visits, the patient returned on a separate day to ensure that any change in airflow did not affect the FE NO measurements.
Each sensor had a capacity to be used 300 times. To identify whether reproducibility was dependent on frequency of use rather than the time from manufacture, 6 of the 12 sensors in each of the two Groups were actuated repeatedly between visits, such that a sufficient number of actuations were still available at the final study visit. The remaining 6 (of 12 in each of the two Groups) were used only at the study visits and not in between times.
Statistical analyses were performed to establish the coefficients of variation and the limits of agreement for repeated measurements for each of the sensor-analyser combinations. This was undertaken using variance component models. The limits of agreement were calculated using an extension of Bland Altman analyses in order to accommodate multiple comparisons (23 NIOX MINO Ò sensor-analyser combinations versus NIOX) i.e. 1.96 times the standard deviation of the repeated measurements random factor. In order to assess whether results using any of the NIOX MINO Ò devices were systematically higher or lower than those obtained using the NIOX chemiluminescence analyser, the factor change for each of the sensor-analyser combinations compared to the reference NIOX results was calculated. This was the mean of log 10 FE NO (NIOX)/log 10 FE NO (NIOX MINO Ò ). All calculations were done using Stata V10. Two post hoc analyses were performed. Firstly, we compared the outcomes for subjects with low and high baseline FE NO independently of the Group to which they were initially randomised. Secondly, we compared the CV and limits of agreement between sensors which had been used on multiple occasions between visits with those which had not. This was to ascertain whether multiple uses or prolonged shelf life were factors contributing to changes in sensor reproducibility over time.
Results
Seventeen patients completed the study. In Group 1 (n Z 8), 3 had high FE NO levels and 5 had low FE NO levels. In Group 2 (n Z 9), 6 had high FE NO levels and 3 had low FE NO levels. Overall, there were 9 patients with high FE NO at baseline, and 8 with low FE NO at baseline. Their characteristics are shown in Table 1 . The geometric mean FE NO was 36.4 ppb (95% C.I.: 23.8, 55.6), 36.4 ppb (95% C.I.: 24.4, 54.3), and 33.5 ppb (95% C.I.: 22.3, 50.3) at visits 1, 2 and 3 respectively. The maximum intra-individual change in FE NO (using the NIOX) between any two visits ranged from 2.8 to 66.8 ppb (mean 16.6 AE 15.9 ppb).
One of the 24 NIOX MINO Ò devices (I 21) was withdrawn from further use when it began to yield lower than expected readings and subsequently failed the external quality control check. This was simultaneously identified by the internal quality control check as an "error message". The threshold for the error message was set during manufacture to occur when the measured signal was >10 ppb different from the quality control signal. The performance characteristics of the remaining 23 sensor-analyser combinations in comparison Table 2 . More detailed data are provided in Table 3 .
Overall, the NIOX MINO Ò devices provided data whose reproducibility was within clinically acceptable limits (AE10 ppb). At visit 1, the mean coefficient of variation (CV) for repeated measurements (23 sensor-analyser combinations) was 4.0% (range 1.2e7.2%). There was no significant change in mean CV over time: at visit 2 (approximately one month) the mean CV was 3.6% (range 2.0e7.0) and at visit 3 (approximately two months) it was 3.6% (range 1.6e7.6%). The 95% confidence interval for the limits of agreement for FE NO was similarly stable. At baseline the mean value was AE4.2 ppb (range 0.9e9.6 ppb), at visit 2 it was AE3.8 ppb (range 1.6e6.9 ppb) and at visit 3 it was AE3.2 ppb (range 1.2e6.8 ppb). The overall changes with time were not statistically significant. The number of individual sensoranalyser combinations for which the limits of agreement exceeded the manufacturer's specifications (AE5 ppb for the low FE NO group; AE10% for the high FE NO group) was 0 at visit 1, 3 at visit 2(13%) and 5 at visit 3(22%).
Comparisons for the CV and the 95% confidence intervals for the limits of agreement between patients with high and low baseline FE NO are also shown in Table 2 . Whereas at baseline there were no significant differences, the results at visit 2 and visit 3 were significantly different. The coefficients of variation were significantly lower and the limits of agreement were significantly higher in the high FE NO group (p < 0.001 for both).
Comparisons between the sensor-analyser combinations which were used frequently over the study interval (approximately 270 times) versus those used only intermittently (approximately 100 times) revealed that, at visit 3, there were significant differences in the CV and marginally significant differences in the limits of agreement. In the frequently used devices the CV was 1.6% lower (95% CI -0.6e2.7, p Z 0.005) than in the intermittently used devices. The limits of agreement were AE1.3 ppb lower (95% CI -0.02e2.7, p Z 0.053) in the frequently used devices (see Table 2 ).
Discussion
In this study we evaluated the long term performance characteristics of NIOX MINO Ò , a portable nitric oxide analyser. By Performance characteristics of the NIOX MINO Ò providing data on 23 sensor-analyser combinations, our results answer the questions: on average what is the within-patient performance for any NIOX MINO Ò device which I may be using? And, what might happen to performance characteristics over time or when the sensor is changed?
We found that the mean limits of agreement for repeated within-subject measurements averaged AE 4 ppb, with a maximum of AE9.6 ppb. This is almost identical to the limits of agreement for repeated FE NO measurements in patients with stable asthma first reported by Kharitonov et al. (AE4 ppb) using the NIOX Ò chemiluminescence analyser. 20 In our study, the CV was approximately 4% with a maximum of 8% which is less than the changes in FE NO which are considered clinically important (AE40% 4 ). Thus, overall, the performance characteristics of the NIOX MINO Ò were satisfactory. However, for some individual sensoranalyser combinations, the manufacturer's specified limits of agreement (AE5 ppb for patients with low FE NO and AE10% for those with high FE NO ) were exceeded. This occurred in 0 devices at visit 1, 3(13%) at one month, and 5(22%) at two months. Using clinical rather than technical criteria for the threshold at which quality control was assessed (AE10 ppb), one device failed and was withdrawn from further use. This occurred after approximately 3 months. Thus the overall judgment on the performance characteristics of the MINO is related to what is deemed to be an acceptable threshold for reproducibility (AE5 ppb or AE 10 ppb).
Our data extend the results of previous investigations.
5,9e19 Alving et al. reported 95% limits of agreement of À9.8 to þ8.0 ppb, 9 while Boot et al. reported limits of agreement of À9.5 to þ7.4 ppb 10 In most studies using the NIOX MINO Ò , the limits of agreement for within-subject comparisons against a chemiluminescence analyser have been similar (maximum AE 9.6 ppb). However, almost all of them used only single NIOX MINO Ò devices in their comparisons, and no distinctions were made between the sensor and the analyser. For example, Menzies et al., 16 compared a single NIOX MINO Ò device against the NIOX Ò in 151 subjects, but unfortunately the sensors were changed periodically. The total number of sensors used and the time at which they were replaced was not stated. In the study by Khalili et al. 14 three NIOX MINO Ò devices were used in 110 subjects, but no between-device comparisons were made in their analyses. In the present study, a total of 23 sensor-analyser combinations were tested without any of the sensors being changed during the course of the study. This approach ensured that any between-sensor variation was accounted for.
As far as we are aware, this is the first study to evaluate the stability of the NIOX MINO Ò over time. This is important for NO analysers based on electrochemical technology. Firstly, we conducted measurements using multiple sensor-analyser combinations at baseline, and at one month and two months. As can be seen from Table 2 , there was no evidence of a systematic change in performance with time, although there was an increase from zero in the number of devices which exceeded the performance limits set by the manufacturer. We also explored the possibility that reproducibility might vary depending on frequency of use rather than in relation to chronological age. This was found to be the case: the CV and the limits of agreement were significantly different at two months in devices which were used frequently (up to 270 times) compared to those which were not (up to 100 times). However, the magnitude of the difference was not clinically important (<10 ppb).
Previous authors have indicated the possibility of systematic bias when comparing FE NO values obtained using the NIOX MINO Ò against those obtained using chemiluminescence analysers. 5, 10, 13, 15, 18 In one report FE NO measurements were so much higher with the NIOX MINO Ò that a correction factor was recommended. 18 However, in these reports the results were obtained using one NIOX MINO Ò device only. In our study, although results from all 23 NIOX MINO Ò sensor-analyser combinations were on average higher than those obtained using the NIOX Ò (i.e. factor change <1.0, see Table 2 ), the pattern was not consistent and the differences were not significant. In our study, the differences between the NIOX Ò and the NIOX MINO Ò ranged maximally from À4% to þ6% (NS). We cannot account for the very large between-device difference reported by Pizzimenti et al. 18 It has been reported that CVs and limits of agreement are greater when measuring high rather than low FE NO values. 15 Persistently high FE NO may occur in some patients even with well controlled asthma, and changes over time may be more important than absolute values, hence the importance of obtaining reproducible results. 22 Our data showed that the limits of agreement were significantly higher in the high FE NO group (>50 ppb). The mean values for the limits of agreement were acceptable (<10 ppb), but the 95% confidence intervals for the limits of agreement extended to 19.8 ppb (see Table 2 ). This indicates that when measuring FE NO in patients for whom the value is high, % change rather than absolute change is more reliable.
The implications of these data depends on the setting in which the NIOX MINO Ò is being used. For the clinician, single measurements may be used diagnostically, and depend on the relationship between the measured value and specific cut-points (25 ppb and 50 ppb respectively 1 ). The clinician has to consider whether allowing for variation of AE10 ppb will render a particular result either falsely negative or falsely positive. When monitoring asthma, changes in FE NO over time are more important. In this regard, even if an electrochemical sensor demonstrates "signal drift" over time, the "drift" as reported in this paper, is generally less than the changes which are deemed to be clinically significant (30e40%). 4, 23 For research purposes, quality control should be more rigorous, and we recommend that for multicentre or longitudinal studies, each sensor/analyser combination ought to be validated against a calibrated chemiluminescence analyser, and validation procedures, as described above, should be repeated at regular intervals during the lifetime of each sensor.
In summary, the reproducibility of FE NO values measured in 23 NIOX MINO Ò nitric oxide analysers was generally within prescribed limits and stable over time. The overall outcomes did not differ significantly in patients with high FE NO levels. Although differences in longitudinal reproducibility emerged in devices which were used infrequently between testing, and in 22% of sensor-analyser combinations the results were outside the manufacturer's specifications at 2 months, they remained within AE10 ppb of the "gold standard".
